Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.04.2021 | Case report

Trametinib/vemurafenib

Generalised maculopapular rash with pruritis following off-label use and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bourque MS, et al. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric Blood and Cancer 68: No. 4, Apr 2021. Available from: URL: http://doi.org/10.1002/pbc.28814 Bourque MS, et al. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric Blood and Cancer 68: No. 4, Apr 2021. Available from: URL: http://​doi.​org/​10.​1002/​pbc.​28814
Metadaten
Titel
Trametinib/vemurafenib
Generalised maculopapular rash with pruritis following off-label use and lack of efficacy: case report
Publikationsdatum
01.04.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-94436-2

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Tocilizumab

Case report

Penicillamine

Case report

Dupilumab